Vertex Pharmaceuticals (VRTX) reachead $475.49 at the closing of the latest trading day, reflecting a -1.41% change compared to its last close. Contrary to what you might read on social media ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...